DDInter915 DDInter1059
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults. While levomilnacipran was previously investigated and proposed as a potential treatment for stroke in Europe, the EMA decided against this use.
Indacaterol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Levomilnacipran
Indacaterol {u} (Compound) causes {v} (Side Effect) Infection
Infection {u} (Side Effect) is caused by {v} (Compound) Levomilnacipran
Indacaterol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Ticagrelor
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levomilnacipran
Indacaterol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Meperidine
Meperidine {u} (Compound) resembles {v} (Compound) Levomilnacipran
Indacaterol {u} (Compound) causes {v} (Side Effect) Infection
Infection {u} (Side Effect) is caused by {v} (Compound) Milnacipran
Milnacipran {u} (Compound) resembles {v} (Compound) Levomilnacipran
Indacaterol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levomilnacipran
Indacaterol {u} (Compound) causes {v} (Side Effect) Infection
Infection {u} (Side Effect) is caused by {v} (Compound) Treprostinil
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levomilnacipran
Indacaterol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is palliated by {v} (Compound) Pseudoephedrine
Pseudoephedrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levomilnacipran
Indacaterol {u} (Compound) binds {v} (Gene) ADRB2
ADRB2 {u} (Gene) is downregulated by {v} (Compound) Treprostinil
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levomilnacipran
Indacaterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Adrenergic beta2-Agonists {u} (Pharmacologic Class) includes {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levomilnacipran
Indacaterol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Levomilnacipran (Compound)
Indacaterol (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Levomilnacipran (Compound)
Indacaterol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ticagrelor (Compound) and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Indacaterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Meperidine (Compound) and Meperidine (Compound) resembles Levomilnacipran (Compound)
Indacaterol (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Milnacipran (Compound) and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Indacaterol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Indacaterol (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Treprostinil (Compound) and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Indacaterol (Compound) treats asthma (Disease) and asthma (Disease) is palliated by Pseudoephedrine (Compound) and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Indacaterol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is downregulated by Treprostinil (Compound) and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Indacaterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran